One study at MSK reported that EOPC (n = 95; ≤55 years) patients had higher frequency of SMAD4 mutations than patients with average‐onset pancreatic cancer (AOPC; n = 203, ≥70 years).42 Here, SMAD4 is linked to pancreatic neoplasm.